[144] Takeda Pharmaceutical Company Limited American SEC Filing

Rhea-AI Filing Summary

Takeda Pharmaceutical Company Limited (TAK) has filed a Form 144 indicating an intended sale of 58,559 American Depositary Shares (ADSs), representing approximately 0.05 % of the company’s 123,490,548 ADSs outstanding. The proposed transaction is valued at US $902,979.78 based on the market price at the time of filing and is expected to take place on or about 07 / 09 / 2025 through NYSE, with Interactive Brokers LLC acting as broker.

The shares stem from restricted stock units that vested on 07 / 01 / 2025. The filer reports no sales of Takeda securities in the preceding three months. By signing the notice, the seller certifies the absence of undisclosed material adverse information about Takeda and affirms compliance with Rule 144 and, if applicable, any Rule 10b5-1 trading plan.

While the dollar amount is modest relative to Takeda’s market capitalization, Form 144 filings alert investors to potential insider activity that could influence near-term trading volume and sentiment.

Positive

• None.

Negative

• Insider intends to sell 58,559 ADSs worth approximately US$903 k, which can be perceived as a modest negative signal, though the scale is immaterial (<0.05 % of shares outstanding).

Insights

Financial Analyst

TL;DR – Minor insider sale (~US$0.9 m) equals just 0.05 % of ADS float; limited valuation impact.

The Form 144 discloses a forthcoming disposition of 58,559 Takeda ADSs worth about US$903 k. Relative to the 123.5 m ADSs outstanding, the transaction is immaterial and unlikely to exert meaningful downward pressure on share price. The shares originate from recently vested RSUs, a routine source of insider liquidity. No other sales were reported in the last three months, lessening concerns about a broader sell-off. Overall, I view the filing as informational rather than impactful.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares (ADSs)	Interactive Brokers LLC One Pickwick Plaza Greenwich CT 06830	58559	902979.78	123490548	07/09/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADSs	07/01/2025	Restricted Stock Unit Awards - Vested.	Takeda Pharmaceutical Company Limited			118668	07/01/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What quantity of Takeda (TAK) shares is being sold under this Form 144?

The filing covers 58,559 American Depositary Shares (ADSs).

What is the approximate market value of the proposed Takeda share sale?

The aggregate market value disclosed is US $902,979.78.

When is the intended sale date for the 58,559 Takeda ADSs?

The filer lists an approximate sale date of 07 / 09 / 2025.

How large is this transaction relative to Takeda’s outstanding ADSs?

It represents roughly 0.05 % of the 123,490,548 ADSs outstanding.

What was the source of the shares being sold?

They were obtained via restricted stock unit (RSU) awards that vested on 07 / 01 / 2025.

Which broker will handle the transaction?

Interactive Brokers LLC, One Pickwick Plaza, Greenwich, CT 06830.